gotop

News

  • link
    GNTbm announces licensing of exclusive sales/marketing rights of anticancer drug Chidamide to Taiwan Specialty Pharma Corp. (TSPC)
    GNT Biotech & Medicals Co., Ltd. (GNTbm, TPEx Emerging: 7427) announced that it has awarded exclusive sales and marketing rights in Taiwan of anticancer drug Chidamide to pharmaceutical distribution company Taiwan Specialty Pharma Corp. (TSPC)
    2018-06-21
  • link
    GNTbm to begin Phase III clinical trial in Taiwan of Chidamide for breast cancer
    GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer
    2017-04-19
  • link
    GNTbm Exhibits at the 2016 BIO
    GNTbm Exhibits at the 2016 BIO
    2016-06-04
  • link
    GNTbm Updates Developments in the Vaucarrin® Nanogold Drug Delivery Platform
    GNTbm Updates Developments in the Vaucarrin® Nanogold Drug Delivery Platform
    2015-09-01
  • link
    GNT Biotech and Medicals Corporation Licenses Novel Cancer Molecule from Shenzhen Chipscreen Biosciences Ltd.
    GNT Biotech and Medicals Corporation Licenses Novel Cancer Molecule from Shenzhen Chipscreen Biosciences Ltd.
    2013-10-10